RVL Pharmaceuticals plc Ordinary Shares
RVLP
RVLP was delisted on the 20th of October, 2023.
55 hedge funds and large institutions have $25.6M invested in RVL Pharmaceuticals plc Ordinary Shares in 2021 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 20 increasing their positions, 16 reducing their positions, and 13 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 16
8% less funds holding
Funds holding: 60 → 55 (-5)
17% less capital invested
Capital invested by funds: $31M → $25.6M (-$5.31M)
38% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$2.84M |
| 2 |
SCM
Sio Capital Management
New York
|
+$2.13M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.68M |
| 4 |
Squarepoint
New York
|
+$683K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$231K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$2.31M |
| 2 |
DCM
DG Capital Management
New York
|
-$2.11M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$734K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$346K |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$257K |
RVLP Hedge Fund Activity: Q1 2021 in Review
55 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q1 2021, worth a combined $25.6M — down 17% from $31M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of RVLP and 8 opened new positions — a net loss of 5 holders — while 16 trimmed existing stakes and 20 added.
The largest buyer was Morgan Stanley, adding an estimated $2.84M. The largest seller was Magnetar Financial, exiting entirely with an estimated $2.31M sold.
- 55 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q1 2021, down from 60 in Q4 2020.
- Funds reported $25.6M of RVL Pharmaceuticals plc Ordinary Shares stock for Q1 2021, down 17% quarter-over-quarter.
- 8 funds opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q1 2021 and 13 closed out, a net change of -5 holders.
- The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q1 2021 was Morgan Stanley, an estimated $2.84M added.
- The largest RVL Pharmaceuticals plc Ordinary Shares seller in Q1 2021 was Magnetar Financial, an estimated $2.31M sold.
Based on aggregated 13F filings for Q1 2021.